2022 Riverina Nurse Melanoma Symposium

Join us for an engaging educational program designed for all nurses who care for melanoma patients. 

Hosted by Amie St Clair, now part of Melanoma Institute Australia, our one-day symposium will give you practical insights from multidisciplinary local experts, including an opportunity to network with your fellow nurses and learn about services in the Riverina region.

The 2022 Riverina Nurse Melanoma Symposium program covers the whole spectrum of the disease including diagnosis, management of early and late stage melanoma (with a key focus on immunotherapy) and supportive care.

PROGRAM

• Welcome (Annette St Clair and Danielle Goss)
• What is melanoma? Initial assessment and diagnosis (Dr Gracie Gouda - GP)
  
• The importance of the pathologist in the treatment of melanoma (Dr Kirstin McKenzie - Pathologist)
  
• Surgical management of Stage 0-IV melanoma (A/Prof Richard Harrison - Surgeon)
• Surgical complications and management (Carlie Davis and Karyn Bowering, CNCs)
• Lymphoedema: What is it and how do we treat it? (Stuart McKenzie - Physiotherapist)
• Medical management of Stage III–IV melanoma (Dr Piyush Grover - Medical Oncology Fellow)
• Adverse side effects: How do nurses manage in the rural setting? (Rebecca Johnson - CNC)
  
• Survivorship - I’ve survived... Now what? (Dr Skye Dong - Clinical Psychologist)

(Please note this Program is subject to change)

Refreshments will be provided. Registration will open at 8:30am with the event commencing at 9am. 

Cost: $60 (inc GST)

CPD: A Certificate of Attendance will be given to attendees. 

RSVP: By 13 October 2022.

Safety at our event: Please follow COVID-safe practices when attending our event and stay home if you are feeling unwell. If you can no longer attend due to COVID-19, please contact us.

Download the flyer

This educational event is an initiative of Amie St Clair part of Melanoma Institute Australia.

MIA’s Education Program is proudly supported through unrestricted educational grants from: MSD, Bristol Myers Squibb, Novartis and HEINE.